PX11512A (9530) HOT MELT PLASTISOL 9785 Rev B Self-Adhering Plastisol PN0299A BLACK FILTER PLASTISOL

ARTIC BLEND PLASTISOL CYPRESS PLASTISOL 9107-F-2 BLACK PLASTISOL

9402-2 BLACK PLASTISOL PX-9295-E BLACK PLASTISOL PX-12694-A SELF ADHERING PLASTISOL

PX-20487-B/BLACK THERMOSET PLASTISOL PX-19486-C ORANGE RACK PLASTISOL PX-19486-F BLACK RACK PLASTISOL

XP185 PLASTISOL YELLOW XP187 PLASTISOL PURPLE XP188 PLASTISOL PURPLE

CORE™ Non-Phthalate Plastisols Non-Phthalate Vinyl Plastisols: CORE™ Plastisols that provide the durability and flexibility you need without phthalates

CORE™ Vinyl Plastisols CORE™ Bio-based Vinyl Plastisols CORE™ Non-Phthalate Plastisols

Plastisols provided needed quality and performance for this aircraft interior OEM CORE™ Vinyl Plastisols provided a plastisol solution to enhance performance and processing for radiation protection aprons

Color, Additives and Inks Color, Additives and Inks Color, Additives and Inks

D is t. ) R P M P P G K W R F U L A V Y G C P IF F F M C H X L H U N E M N F O E E C L K R A S C L A S H C E G R A A LB Median: 5%Median: 3% Source: Peer data per Bloomberg market data as of February 5, 2021 Avient reflects 2021 estimated revenue of $4,100M and excludes one-time synergy capture CAPEX ($20M) Avient Specialty Formulators Other Chemical/Specialty Companies Free Cash Flow Conversion (1) 2021E (%) Being asset light helps us to generate strong free cash flow that is in line with specialty formulators. Free cash flow conversion calculated as (EBITDA – Capex) / EBITDA Median: 83% Median: 76% HIGH FREE CASH FLOW CONVERSION Avient reflects 2021 estimated EBITDA of $510M and excludes one-time synergy capture CAPEX ($20M) Source: Peer data per Bloomberg market data as of February 5, 2021 85 87 86 86 81 81 59 92 88 81 79 79 79 76 76 75 73 67 67 64 60 7 A vi en t P P G K W R R P M F U L A V Y G C P IF F F M C U N V R H X L E M N B N R E C L C E A S H F O E G R A H U N K R A S C L A L B Source: Peer data per Bloomberg market data as of February 5, 2021 Total Enterprise Value / 2021E EBITDA Our current valuation implies an EBITDA multiple that is significantly below specialty formulator peers and our historic valuations, when the company had considerable exposure to more cyclical and challenging end markets. With the Clariant Masterbatch acquisition and divestment of the PP&S business, our exposure is now concentrated in less-cyclical and high-growth markets, with increased geographic diversification and a more specialized portfolio that can significantly expand EBITDA margins. 27 Avient reflects 2021 estimated EBITDA of $510M OUR VALUATION VERSUS PEERS Avient Specialty Formulators Other Chemical/Specialty Companies 9.5 21.1 13.2 13.2 12.0 12.0 9.7 25.2 23.1 14.7 13.5 12.9 11.0 11.0 11.0 10.2 9.6 9.3 9.3 9.1 8.6 8.3 A vi en t K W R A V Y R P M G C P P P G F U L A L B E C L H X L IF F F M C G R A B N R F O E A S H C E S C L U N V R E M N H U N K R A Median: 11.0xMedian: 12.6x SUMMARY: WHY INVEST IN AVIENT?